FDA gedatolisib coverage for business development, investment, and market access teams
Earlier
High impact AnalysisJun 2, 2026
Celcuity's Gedatolisib: Navigating the Path to Broad FDA Approval in Breast Cancer
FDA · breast cancer · 8 min
Dr. Sarah MitchellCritical impact NewsMay 4, 2026
Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial
Oncology · 3 min
Dr. Emily CarterPopular topics
- Drug Approvals 1,128 articles
- Clinical Trials 634 articles
- Regulatory Updates 687 articles
- FDA News 502 articles
- Press Releases 443 articles
- Oncology 443 articles
- Rare Diseases 141 articles
Explore intelligence
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways